Molecure to regain worldwide rights to dual chitinase inhibitor OATD-01

– Follows an ongoing strategic portfolio review by partner Galapagos – Molecure to regain all rights, associated data, IP and inventory to OATD-01 – Evaluating potential first indication and development plan for the asset in sarcoidosis WARSAW, June 23, 2022 /PRNewswire/ — Molecure S.A….